NXTCL — NextCell Pharma AB Cashflow Statement
0.000.00%
- SEK81.86m
- SEK47.74m
- SEK10.66m
Annual cashflow statement for NextCell Pharma AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -17.7 | -24.8 | -35 | -41 | -43.2 |
Depreciation | |||||
Non-Cash Items | -0.029 | 0 | — | — | — |
Unusual Items | |||||
Changes in Working Capital | -1.63 | -1.19 | 1.25 | -3.27 | 4.42 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -19 | -25.6 | -33.3 | -43.8 | -37.8 |
Capital Expenditures | -0.87 | -5.84 | -9.35 | -4.1 | -0.083 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.28 | 0 | — | -0.003 | -0.001 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Cash from Investing Activities | -0.59 | -5.84 | -9.35 | -4.1 | -0.084 |
Financing Cash Flow Items | 0.441 | -16.1 | 0.608 | 0.836 | -5.46 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 21.4 | 149 | 0.608 | 0.836 | 34.6 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.83 | 117 | -42.1 | -47.1 | -3.23 |